CN108586472A - Amide derivatives and its application as endothelin-receptor antagonists in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension - Google Patents
Amide derivatives and its application as endothelin-receptor antagonists in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension Download PDFInfo
- Publication number
- CN108586472A CN108586472A CN201810560175.6A CN201810560175A CN108586472A CN 108586472 A CN108586472 A CN 108586472A CN 201810560175 A CN201810560175 A CN 201810560175A CN 108586472 A CN108586472 A CN 108586472A
- Authority
- CN
- China
- Prior art keywords
- endothelin
- amide derivatives
- cerebrovascular
- cardiovascular
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A kind of application the invention discloses amide derivatives formula I and its as endothelin-receptor antagonists in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension,Wherein:R1、R2、R3、R4It is independently selected from H, F or CH3.It finds that amide derivatives formula I of the present invention has preferable endothelin receptor antagonizing activity in the contraction experiment for inhibiting Endothelin to induce isolated rabbit aortic annulus, can be used to prepare that treat cardiovascular and cerebrovascular, hypertension, pulmonary hypertension, myocardial infarction, tumour, diabetic complication, nephrosis, asthma and thyroid gland hyperfunction etc. as endothelin-receptor antagonists.
Description
Technical field
The invention belongs to chemical medicine, it is related to a kind of amide derivatives formula I and its as endothelin receptor antagonism
Application of the agent in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension.
Background technology
Cardiovascular and cerebrovascular disease (cardiovascular and cerebrovascular diseases, CCVd) is heart
The general designation of blood vessel and cranial vascular disease refers to hyperlipidemia, blood is sticky, caused by atherosclerosis, hypertension etc.
Heart, brain and the body tissue ischemic or hemorrhagic disease that occur.The death rate of cardiovascular and cerebrovascular disease occupies various diseases
First of, the final cause of the death overwhelming majority is myocardial hypertrophy, heart failure, cerebral apoplexy and fatal arrhythmia.Especially in recent years
The case fatality rate of serious heart failure is high, has formed a problem of international the world of medicine.These diseases lack effective at present
Medicine.
Endothelin (endothelin, ET) be made of 21 amino acid discoveries such as Yanagisawa within 1988 it is more
Peptide is synthesized and is secreted by vascular endothelial cell, cardiac muscle, smooth muscle etc., belongs to sarafotoxin (sarafotoxin) family, has
Powerful contracting blood vessel and rush vascular smooth muscle cells, is a kind of endogenous damage factor, in many hearts, brain, lung, kidney
It is all of great significance in the morbidity of vascular diseases.ET has the shaped body of 3 kinds of forms, is referred to as ET-1, ET-2 and E-3,
ET is acted on through Endothelin-converting Enzyme (ECEs) and activate, the ET of activation and its receptor in conjunction with and play a role, wherein ET1 is existing by force
Strong and lasting vasoconstrictor effects, and be the inflammatory for causing a variety of diseases with cell growth and mitosis characteristic is promoted
The factor.Due to the potential therapeutic value that endothelin antagonist is contained, major drugmaker of the world all energetically puts into endothelium
In the research and development of plain antagonist, the research of endothelin antagonist has become hot spot.The stronger peptides of effect having found
ET antagonists have BQ123, BQ160, FR2139317 etc., but are limited since the oral bioavailability rate of peptide agonist is low
Its application in the angiocardiopathy of palpus long-term administration.Many drugmakers are dedicated to the non-peptides ET antagonisms for having Orally active
The research of agent.The endothelin-receptor antagonists listed have Bosentan, tezosentan, enrasentan, sitaxentan, A Qusheng
Smooth and ambrisentan, in treatment hypertension, pulmonary hypertension, tumour, diabetic complication, myocardial infarction and cerebral angiospasm etc.
Aspect obtains very good effect.
Used in test example of the present invention control drug Bosentan chemical structural formula for:
Invention content
The invention discloses a kind of amide derivatives formula I, structure is:
Wherein:R1、R2、R3、R4It is independently selected from H, F or CH3.The invention further relates to the medicines of the amide derivatives formula I
Acceptable salt or solvate on.
Further, amide derivatives formula I described in some preferred schemes is
The synthetic route that another object of the present invention discloses the amide derivatives formula I is:
Specifically synthetic method is:
1) 3- sulfamoyls propionic acid (compound 1) occurs into the presence of a base with 2,4- dihydroxy-benzoic acids (compound 2)
Ring reacts, and generates (7- hydroxyl -2- oxo -2H- chromene -3- bases) Methanesulfomide (compound 3);
2) in a suitable solvent, compound 3 reacts with iodomethane, generates (7- methoxyl group -2- oxo -2H- colors
Alkene -3- bases) Methanesulfomide (compound 4);
3) in a suitable solvent, compound 4 and iodide react generation (7- methoxyl groups -2,2- dimethyl -
2H- chromene -3- bases) Methanesulfomide (compound 5);
4) compound 5 again with 2,3- dihydros-[1,4] Dioxin simultaneously [2,3-b] pyridine react generation (4- (2,
3- dihydros-[1,4] Dioxin simultaneously [2,3-b] pyridin-7-yl) -7- methoxyl group -2,2- lutidines -3- bases) first
Sulfonamide (compound 6);
5) in a suitable solvent, compound 6 and corresponding acyl chloride reaction, generate corresponding amide product.
Further, the alkali of the use in the step 1) can use potassium carbonate, and cesium carbonate, triethylamine, sodium hydroxide is molten
Liquid or potassium hydroxide solution, sodium carbonate liquor, preferably triethylamine.
Further, the solvent in the step 2) can use n,N-Dimethylformamide (DMF), Dioxane, DMSO,
DMF, acetone etc., preferably acetone;
Further, the solvent in the step 3) can use n,N-Dimethylformamide (DMF), Dioxane, DMSO,
DMF, THF, acetone etc., preferably THF.
Further, solvent can be absolute ethyl alcohol, second eyeball, benzene, toluene, dimethylbenzene, ether, diformazan in the step 5)
Base sulfoxide, n,N-Dimethylformamide (DMF), acetone, pyridine etc., preferably absolute ethyl alcohol.
Another object of the present invention discloses application of the amide derivatives formula I as endothelin-receptor antagonists.
With the relevant disease of endothelin-receptor antagonists such as cardiovascular and cerebrovascular, hypertension, pulmonary hypertension, myocardial infarction, tumour, diabetes
Complication, nephrosis, asthma and thyroid gland are hyperfunction etc..
Pharmaceutically acceptable salt of the present invention refers to the organic salt and inorganic salts of the compounds of this invention.Pharmaceutically may be used
The salt that the nontoxic acid received is formed includes, but is not limited to, inorganic acid salt, such as hydrochloride, hydrobromate, phosphate, sulfuric acid
Salt, perchlorate;Acylate, such as acetate, oxalates, maleate, tartrate, citrate, succinate, the third two
Hydrochlorate;Or these salt are obtained by other methods described in the books or literature such as ion-exchange.Other can pharmaceutically connect
The salt received includes adipate, alginates, ascorbate, aspartate, benzene sulfonate, benzoate, bisulphate,
Borate, butyrate, camphor hydrochlorate, camsilate, cyclopentyl propionate, digluconate, lauryl sulfate, second
Sulfonate, formates, fumarate, gluceptate, glycerophosphate, gluconate, Hemisulphate, enanthate,
Caproate, hydriodate, 2- hydroxy-ethanesulfonate salts, lactobionate, lactate, laruate, lauryl sulfate, apple
Hydrochlorate, mesylate, 2- naphthalene sulfonates, nicotinate, nitrate, oleate, palmitate, pamoate, pectate, persulfuric acid
Salt, 3- phenylpropionic acid salt, picrate, pivalate, propionate, stearate, rhodanate, tosilate, 11
Hydrochlorate, valerate, etc..By including alkali metal, alkaline-earth metal, ammonium and N+ (C1-4 alkane with alkali appropriate salt obtained by the reaction
Base) 4 salt.Water-soluble or oil-soluble or dispersion product can be obtained by quaternization.Can with the alkali metal of forming salt or
Alkaline-earth metal includes sodium, lithium, potassium, calcium, magnesium, etc..Pharmaceutically acceptable salt further comprises appropriate, nontoxic ammonium, season
The amine cation that ammonium salt and gegenions are formed, such as halide, hydroxide, carboxylate, hydrosulphate, phosphoric acid compound, nitre
Acidulants, C1-8 azochlorosulfonate acid compounds and aromatic sulphonic acid compound.
Solvate of the present invention refers to that one or more solvent molecules are formed by with the compound of the present invention and form
Close object.The solvent for forming solvate includes, but is not limited to, water, isopropanol, ethyl alcohol, methanol, dimethyl sulfoxide, ethyl acetate,
Acetic acid and ethylaminoethanol.
Specific implementation mode
Embodiment 1:N- (((4- (2,3- dihydros-[1,4] Dioxin simultaneously [2,3-b] pyridin-7-yl) -7- first
Oxygroup -2,2- lutidines -3- bases) methyl) sulfonyl) and-quinoline-2-formamide synthesis
The synthesis of 1-1, (7- hydroxyl -2- oxo -2H- chromene -3- bases) Methanesulfomide
By 3- sulfamoyls propionic acid (compound 1) (15.0g, 97.94mmol) and 2,4- dihydroxy-benzoic acids (compound 2)
(10.2g, 66.18mmol) is dissolved in acetic anhydride (22.6mL), the careful addition triethylamine (13.2mL) into mixture, and
Mixture is heated 4 hours.After having reacted, cooling is simultaneously diluted with water.The product of precipitation is filtered and is washed with methanol aqueous solution,
Obtain (7- hydroxyl -2- oxo -2H- chromene -3- bases) Methanesulfomide (compound 3), 21.2g, yield 85%.1H-NMR
(400MHz,CDCl3)δ:4.08(s,2H),5.14(s,2H),5.26(s,1H),6.74(s,1H),6.81(d,1H),7.51
(dd,1H),7.60(s,1H).13C-NMR(125MHz,CDCl3)δ:63.62,102.58,112.85,114.47,119.70,
129.31,140.10,156.42,157.32,160.10.LC-MS(ESI,pos,ion)m/z:256[M+H].
The synthesis of 1-2, (7- methoxyl group -2- oxo -2H- chromene -3- bases) Methanesulfomide
At room temperature, in the presence of Anhydrous potassium carbonate (6.3g, 45.58mmol), with being dissolved in acetone (50.0mL)
Methyl iodide (4.0mL) solution and compound 3 (21.2g, 83.06mmol) are reacted one hour, and concentrated solvent is beaten with water, filtering,
Obtain (7- methoxyl group -2- oxo -2H- chromene -3- bases) Methanesulfomide (compound 4), 12.0g, yield 98%.1H-NMR
(400MHz,CDCl3)δ:3.84(s,3H),4.08(s,2H),5.87(s,2H),7.01(dd,1H),7.04(s,1H),7.58
(s,1H),7.68(dd,1H).13C-NMR(125MHz,CDCl3)δ:56.08,63.62,101.23,112.76,113.78,
119.70,128.73,140.10,156.59,157.32,162.49.LC-MS(ESI,pos,ion)m/z:270[M+H].
The synthesis of 1-3, (7- methoxyl group -2,2- dimethyl -2H- chromene -3- bases) Methanesulfomide
Using THF as solvent, compound 4 (12.0g, 44.56mmol) is made to occur with iodide (13g, 78.20mmol)
Reaction flows back 4 hours, and after the completion of reaction, reaction, concentrated solvent, flash column chromatography separation, you can obtain yellow is quenched in acid adding
Solid (7- methoxyl group -2,2- dimethyl -2H- chromene -3- bases) Methanesulfomide (compound 5), 10.5g, yield 83%.1H-NMR(400MHz,CDCl3)δ:1.45(s,6H),3.84(s,3H),4.08(s,2H),4.29(s,2H),6.43(s,1H),
6.65(dd,1H),7.18(s,1H),7.91(dd,2H).13C-NMR(125MHz,CDCl3)δ:27.07,56.08,62.25,
74.02,103.68,105.06,113.29,119.81,124.15,128.02,155.91,161.96.LC-MS(ESI,pos,
ion)m/z:284[M+H].
1-4, (4- (2,3- dihydros-[1,4] Dioxin simultaneously [2,3-b] pyridin-7-yl) -7- methoxyl groups -2,2-
Lutidines -3- bases) Methanesulfomide synthesis
Compound 5 (10.5g, 37.06mmol) is dissolved in anhydrous dichloroethylene (10mL), and is stirred continuously, at 5 DEG C
Under, anhydrous Aluminum chloride (15.0g, 112.5mmol) is added into the solution of above-mentioned stirring, after stirring 0.5 hour, 2,3- bis- is added
Mixture simultaneously [2,3-b] pyridine (25g, 182.3mmol) and is stirred 12 by hydrogen-[Isosorbide-5-Nitrae] Dioxin at 50-60 DEG C
Hour.It is then added into the mixture of ice and concentrated hydrochloric acid (13mL) to quench the reaction.By organic layer separation and by water layer
It is extracted again with dichloromethane (2*25mL).Combined extract is washed with sodium bicarbonate (50mL), is dried with anhydrous sodium sulfate,
It filters and evaporates.Obtained crude on silica gel chromatographs to obtain thick liquid (4- (2,3- dihydros-[1,4] Dioxins
And [2,3-b] pyridin-7-yl) -7- methoxyl group -2,2- lutidines -3- bases) Methanesulfomide (compound 6), 11.8g, yield
75.5%.1H-NMR(400MHz,CDCl3)δ:1.35(s,6H),3.20(dd,1H),3.42-3.56(m,2H),3.83(s,
3H),4.26(s,6H),4.49(d,1H),6.51(dd,1H),6.55(s,1H),7.16(s,1H),7.21(d,1H),7.48
(s,1H).13C-NMR(125MHz,CDCl3)δ:25.75,41.85,50.49,53.73,56.08,60.15,61.57,77.15,
103.64,105.65,118.36,119.13,123.96,128.30,138.29,140.42,151.20,154.65,
161.83.LC-MS(ESI,pos,ion)m/z:421[M+H].
1-5, N- (((4- (2,3- dihydros-[1,4] Dioxin simultaneously [2,3-b] pyridin-7-yl) -7- methoxyl groups -
2,2- lutidines -3- bases) methyl) sulfonyl) and-quinoline-2-formamide synthesis
Compound 6 (11.8g, 28.06mmol) is added in absolute ethyl alcohol (150mL), quinoline -2- is then gradually added into
Formyl chloride (35mmol), stirring are warming up to reaction reflux.It reacts and finishes after about 8 hours, TLC monitors reaction end.By reaction solution
Stand it is cooling after, filter, a small amount of absolute ethyl alcohol be used in combination to wash filter cake, obtain white solid product N- (((4- (2,3- dihydros-[1,
4] Dioxin simultaneously [2,3-b] pyridin-7-yl) -7- methoxyl group -2,2- lutidines -3- bases) methyl) sulfonyl)
Quinoline-2-formamide, 15.18g, yield 94%.1H-NMR(400MHz,CDCl3)δ:1.36(s,6H),3.20(dd,1H),
3.45-3.58(m,2H),3.83(s,3H),4.27(s,4H),4.50(d,1H),6.51-6.55(m,2H),7.17-7.22(m,
2H),7.55-7.72(m,4H),7.84-7.88(m,2H),8.18(d,1H),8.57(d,1H).13C-NMR(125MHz,
CDCl3)δ:25.75,41.85,52.81,54.09,56.08,60.15,61.57,77.15,103.64,105.65,118.36,
118.55,119.13,123.96,127.4,127.61,127.87,128.3,129.56,130.61,137.46,138.29,
140.42,141.05,151.2,153.85,154.65,157.93,161.83.LC-MS(ESI,pos,ion)m/z:576[M+
H]。
Embodiment 2:N- (((4- (2,3- dihydros-[1,4] Dioxin simultaneously [2,3-b] pyridin-7-yl) -7- first
Oxygroup -2,2- lutidines -3- bases) methyl) sulfonyl) and-(the fluoro- quinoline of 4-) -5- formamides synthesis
Compound 6 (11.8g, 28.06mmol) is added in absolute ethyl alcohol (150mL), is then gradually added into that (4- is fluoro-
Quinoline) -5- formyl chlorides (35mmol), stirring, which is warming up to, reacts reflux.It reacts and finishes after about 8 hours, TLC monitors reaction end.
It after reaction solution is stood cooling, filters, a small amount of absolute ethyl alcohol washing filter cake is used in combination, obtains white solid product N- (((4- (2,3-
Dihydro-[1,4] Dioxin simultaneously [2,3-b] pyridin-7-yl) -7- methoxyl group -2,2- lutidines -3- bases) first
Base) sulfonyl)-(the fluoro- quinoline of 4-) -5- formamides, 15.82g, yield 95%.LC-MS(ESI,pos,ion)m/z:594[M+
H]。
Embodiment 3:N- (((4- (2,3- dihydros-[1,4] Dioxin simultaneously [2,3-b] pyridin-7-yl) -7- first
Oxygroup -2,2- lutidines -3- bases) methyl) sulfonyl) and-(4- Methyl-quinolines) -5- formamides synthesis
Compound 6 (11.8g, 28.06mmol) is added in absolute ethyl alcohol (150mL), (4- first is then gradually added into
Yl-quinoline) -5- formyl chlorides (35mmol), stirring, which is warming up to, reacts reflux.It reacts and finishes after about 8 hours, TLC monitorings reaction is eventually
Point.It after reaction solution is stood cooling, filters, a small amount of absolute ethyl alcohol washing filter cake is used in combination, obtains white solid product N- (((4-
(2,3- dihydros-[1,4] Dioxin simultaneously [2,3-b] pyridin-7-yl) -7- methoxyl group -2,2- lutidines -3-
Base) methyl) sulfonyl)-(4- Methyl-quinolines) -5- formamides, 15.06g, yield 91%.LC-MS(ESI,pos,ion)m/z:
590[M+H]。
Embodiment 4:N- (((4- (2,3- dihydros-[1,4] Dioxin simultaneously [2,3-b] pyridin-7-yl) -7- first
Oxygroup -2,2- lutidines -3- bases) methyl) sulfonyl) and-(4,5- difluoro-quinolins) -5- formamides synthesis
Compound 6 (11.8g, 28.06mmol) is added in absolute ethyl alcohol (150mL), is then gradually added into (4,5- bis-
Fluoro- quinoline) -5- formyl chloride 35mmol), stirring is warming up to reaction reflux.It reacts and finishes after about 8 hours, TLC monitorings reaction is eventually
Point.It after reaction solution is stood cooling, filters, a small amount of absolute ethyl alcohol washing filter cake is used in combination, obtains white solid product N- (((4-
(2,3- dihydros-[1,4] Dioxin simultaneously [2,3-b] pyridin-7-yl) -7- methoxyl group -2,2- lutidines -3-
Base) methyl) sulfonyl)-(4,5- difluoro-quinolin) -5- formamides, 16.48g, yield 96%.LC-MS(ESI,pos,ion)m/
z:612[M+H]。
Embodiment 4:N- (((4- (2,3- dihydros-[1,4] Dioxin simultaneously [2,3-b] pyridin-7-yl) -7- first
Oxygroup -2,2- lutidines -3- bases) methyl) sulfonyl) and-(3- methyl-isoxazole) -5- formamides synthesis
Compound 6 (11.8g, 28.06mmol) is added in absolute ethyl alcohol (150mL), (3- first is then gradually added into
Base-isoxazole) -5- formyl chloride 35mmol), stirring is warming up to reaction reflux.It reacts and finishes after about 8 hours, TLC monitorings reaction is eventually
Point.It after reaction solution is stood cooling, filters, a small amount of absolute ethyl alcohol washing filter cake is used in combination, obtains white solid product N- (((4-
(2,3- dihydros-[1,4] Dioxin simultaneously [2,3-b] pyridin-7-yl) -7- methoxyl group -2,2- lutidines -3-
Base) methyl) sulfonyl)-(3- methyl-isoxazole) -5- formamides, 12.93g, yield 87%.LC-MS(ESI,pos,ion)m/
z:530[M+H]。
Test example 1:Inhibit the contraction of Endothelin induction isolated rabbit aortic annulus
Normal rabbits auricular vein pneumatic needl opens chest after putting to death, take out aorta pectoralis, separation.It is placed in 4 containing saturated oxygen
Connective tissue is removed in DEG C cold K-H liquid.Gently rubbed removal endarterium epithelial cell with cotton thread.It is cut into the vascular circle of 4-6mm,
It hangs in the 8mL baths containing K-H buffer salt solutions, leads to pure O2, pH7.4,37 DEG C of constant temperature.Adjusting rest tension is 2g, balance
60min。
ET-1 (10 is added-8Mol/L final concentrations), 40min is incubated when vessel retraction reaches maximum tension, administration group difference
Test-compound (10 is added-6Mol/L final concentrations), if solvent group is control.Observe its vessel retraction to Endothelin in 40min
The antagonism of reaction.The calculating of endothelin antagonist inhibiting rate:ET-1 to vessel retraction 40min when tension be A (g),
Test-compound (10-6Mol/L final concentrations) be incubated 40min after vessel retraction tension be B (g), then its inhibit percentage be (A-
B)/A × 100%.(N=6)
Table 1ERA induces rabbit myocardium vessel tension variation to ET-1
Amide derivatives formula I of the present invention has preferable endothelin receptor antagonizing activity, can be used as Endothelin
Receptor antagonist be used to prepare treatment cardiovascular and cerebrovascular, hypertension, pulmonary hypertension, myocardial infarction, tumour, diabetic complication,
Nephrosis, asthma and thyroid gland are hyperfunction etc..
Claims (5)
1. a kind of general formula structure is the amide derivatives and its pharmaceutically acceptable salt or solvate of formula I
Wherein:R1、R2、R3、R4It is independently selected from H, F or CH3。
2. amide derivatives formula I as described in claim 1, characterized in that be selected from following compound:
3. application of the amide derivatives formula I as claimed in claim 1 or 2 as endothelin-receptor antagonists.
4. application of the amide derivatives formula I as claimed in claim 1 or 2 in the drug for preparing cardiovascular and cerebrovascular disease.
5. amide derivatives formula I as claimed in claim 1 or 2 is preparing cardiovascular and cerebrovascular, hypertension, pulmonary hypertension, the heart
Application in the hyperfunction drug of flesh infarct, tumour, diabetic complication, nephrosis, asthma, thyroid gland.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810560175.6A CN108586472A (en) | 2018-06-03 | 2018-06-03 | Amide derivatives and its application as endothelin-receptor antagonists in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810560175.6A CN108586472A (en) | 2018-06-03 | 2018-06-03 | Amide derivatives and its application as endothelin-receptor antagonists in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108586472A true CN108586472A (en) | 2018-09-28 |
Family
ID=63630863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810560175.6A Withdrawn CN108586472A (en) | 2018-06-03 | 2018-06-03 | Amide derivatives and its application as endothelin-receptor antagonists in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108586472A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106687465A (en) * | 2014-06-11 | 2017-05-17 | 维纳拓尔斯制药公司 | Beta-lactamase inhibitors |
CN107759652A (en) * | 2017-08-30 | 2018-03-06 | 大连理工大学 | Containing cholesteric coumarin derivatives and its synthesis and application |
-
2018
- 2018-06-03 CN CN201810560175.6A patent/CN108586472A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106687465A (en) * | 2014-06-11 | 2017-05-17 | 维纳拓尔斯制药公司 | Beta-lactamase inhibitors |
CN107759652A (en) * | 2017-08-30 | 2018-03-06 | 大连理工大学 | Containing cholesteric coumarin derivatives and its synthesis and application |
Non-Patent Citations (1)
Title |
---|
FILIPE AREIAS ET AL.: "New chromene scaffolds for adenosine A2A receptors: Synthesis, pharmacology and structureeactivity relationships", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102187608B1 (en) | SSAO inhibitor | |
JP2020521770A (en) | Lactam compounds as FXR receptor agonists | |
CA2693552A1 (en) | Pyridone compound | |
CN105085322B (en) | The Preparation Method And Their Intermediate of the intermediates of AHU 377 and the preparation method of intermediate | |
CN104245663B (en) | bicyclic compound | |
TWI801394B (en) | Coumarin ring-like compounds as mek inhibitor and application thereof | |
CN116082303A (en) | Novel oxopyridines, intermediates and uses thereof | |
US20050004191A1 (en) | Novel processes for making- and a new crystalline form of- leflunomide | |
CN116262736A (en) | Novel oxo-pyridine compound and preparation method and application thereof | |
CN108570055A (en) | A kind of amide derivatives and its application in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension | |
EP4286371A1 (en) | Pyrazolamide derivative, preparation method therefor, and application thereof | |
CN111499591A (en) | ROR gamma modulators | |
CN108586472A (en) | Amide derivatives and its application as endothelin-receptor antagonists in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension | |
CN108570056A (en) | A kind of amide derivatives and its application in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension | |
CN108658958A (en) | A kind of amide derivatives and its application as endothelin-receptor antagonists | |
CN108586445A (en) | Amide derivatives and its application as endothelin-receptor antagonists in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension | |
WO2017101881A1 (en) | Ginkgolide b derivative and preparation method and use thereof | |
JPH07267954A (en) | New 3-phenylsulfonyl-3,7-diazabicyclo(3,3,1)nonane compound,its production, and antiarrhythmic agent | |
CN106831475B (en) | The preparation method and application of 2- lacto benzoic acid | |
CN103833730B (en) | Benzo five-membered Azacyclyl piperidine derivative, Its Preparation Method And Use | |
NO744175L (en) | ||
CN106420754B (en) | The purposes of benzo five-membered Azacyclyl bridged piperazine derivatives | |
CN111039880A (en) | Application of miconazole and derivative thereof as TGR5 agonist | |
CN111057069B (en) | Cyclic compound, application and composition thereof | |
NO752109L (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180928 |